China SXT Pharmaceuticals, Inc., a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces, including Advanced TCMPs, fine TCMPs, regular TCMPs, and TCM Homologous Supplements announced that an 1 for 20 reverse split of its ordinary shares was approved by the Company’s board of directors on May 10, 2022 and became effective on May 17, 2022.
TAIZHOU, China, May 18, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (“China SXT” or the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”) announced today that an 1 for 20 reverse split of its ordinary shares was approved by the Company’s board of directors on May 10, 2022 and became effective on May 17, 2022. . In connection with the reverse share split, the Company’s shareholders will receive one new ordinary share of the Company for every twenty shares they hold. The Company’s ordinary shares is expected to begin trading on a split-adjusted basis when the market opens on May 19, 2022,
The reverse share split is expected to lead the Company’s ordinary shares to trade at approximately twenty times the price per share at which it trades prior to the effectiveness of the reverse share split. The Company, however, cannot assure that the price of its ordinary shares after the reverse split will reflect the 1 for 20 reverse split ratio, that the price per share following the effective time of the reverse split will be maintained for any period of time, or that the price will remain above the pre-split trading price.
The Company has filed the Amended and Restated Articles and Memorandum of Association in connection with the reverse share split. As of May 16, 2022, there were approximately 40,627,868 of the Company’s ordinary shares outstanding. Effecting the 1 for 20 reverse split will reduce that amount to approximately 2,031,400. The reverse split will not change the number of the Company’s authorized preferred and ordinary shares, which will remain as unlimited.
Treatment of Stock Options and Restricted Shares
The number of ordinary shares into which the Company’s outstanding stock options and restricted shares as well as the options’ relevant exercise price per share will be proportionally adjusted to reflect the reverse split.
Fractional Shares
Any fractional shares that would have resulted because of the Reverse Split will be rounded up to the nearest whole share.
New Ordinary Share Certificates
Certificates reflecting the new share number will be issued in due course as old share certificates are tendered for exchange or transfer to the Company’s transfer agent, TranShare. Registered shareholders holding pre-split shares of the Company’s ordinary shares electronically in book-entry form are not required to take any action to receive post-split shares. Shareholders who hold their shares through a securities broker or nominee (i.e., in “street name”) will be contacted by their brokers or nominees with any instructions. For more information, shareholders and securities brokers should contact TranShare at (303)662-1112.
About China SXT Pharmaceuticals, Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com.
Safe Harbor Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Specifically, the Company’s statements regarding the closing of the proposed private placement are forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; the growth of the pharmaceutical market, particularly the Traditional Chinese Medicine Pieces (“TCMPs”) market, in China; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company serves and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward - looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Name: Feng Zhou
Email: fzhou@sxtchina.com
